Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Kidney Cancer treatment details. Immunotherapy. University of Washington, Seattle, Washington, United States

Survival: N/R
Toxicity Grade: 3
Treatments: Immunotherapy
Country: United States
City/State/Province: Seattle, Washington
Hospital: University of Washington
Journal: Link
Date: 9/2003

Patients: This Phase I study involved 26 patients with metastatic renal cell carcinoma; 19 men and 7 women. Median age was 58. Sites of metastasis included bone, liver, lung, lymph nodes, and other sites.

Treatment: The treatment consisted of CD3/CD28-activated T cells and Interleukin-2. (CD3/CD28-activated T cells are T cells from the individual patients that have been activated and expanded outside their bodies using antibodies to CD3 and CD28 coimmobilized on magnetic beads.)

Toxicity: Grade 3 toxicities included asthenia, fever, chills, anorexia, pain, diarrhea, and constipation.

Results: The median survival was 21 months even though there were no complete or partial responses.

Support: The study was supported by Xcyte Therapies, Inc. This company owns the process to produce activated T-cells as used in the study.

Correspondence: John A Thompson, MD

E-mail to a Friend Email Physician More Information